NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today reported financial results for the three months and full year ended December 31, 2016 and provided other general business updates.
“2016 was a truly momentous year for Intercept, marked by the U.S. and European approvals of Ocaliva for the treatment of primary biliary cholangitis (PBC),” said Mark Pruzanski, M.D., President and CEO of Intercept. “We successfully transitioned to a commercial organization with our U.S. launch for PBC in June 2016 that generated net sales of $18.2 million for the year, while making solid progress in our clinical development programs.”
“2016 was a truly momentous year for Intercept, marked by the U.S. and European approvals of Ocaliva for the treatment of primary biliary cholangitis (PBC),” said Mark Pruzanski, M.D., President and CEO of Intercept. “We successfully transitioned to a commercial organization with our U.S. launch for PBC in June 2016 that generated net sales of $18.2 million for the year, while making solid progress in our clinical development programs.”
